Related Experiment Video
Updated: May 24, 2026
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Angiogenesis inhibition using an oncolytic herpes simplex virus expressing endostatin in a murine lung cancer model
Jonathan M Goodwin1, Anthony D Schmitt, Christopher M McGinn
1Division of Thoracic Surgery, Massachusetts General Hospital Cancer Center, Boston, USA.
Abstract:
Herpes-mediated viral oncolysis alone is not sufficient to completely eradicate tumors. In this study we used a replication conditional, endostatin-expressing herpes simplex virus-1 mutant (HSV-Endo) in a murine lung cancer model. We hypothesized that the anti-angiogenic action of endostatin would improve upon the oncolytic effect of HSV-1. HSV-Endo was evaluated in a pulmonary metastases and orthotopic flank model, where there was significantly less tumor burden and reduced microvessel density compared to a control virus. Endostatin expression appears to improve the anti-tumor effect of HSV-1 in a lung cancer model.
Insights
This study combined herpes simplex virus-1 (HSV-1) with endostatin to enhance oncolysis in lung cancer. The engineered virus significantly reduced tumor burden and microvessel density in mice.
Area of Science:
- Oncology
- Virology
- Gene Therapy
Background:
- Herpes simplex virus-1 (HSV-1) oncolysis shows promise but is insufficient for complete tumor eradication.
- Tumor angiogenesis is a critical factor in cancer progression and metastasis.
Purpose of the Study:
- To evaluate the efficacy of a replication-conditional, endostatin-expressing HSV-1 mutant (HSV-Endo) in a murine lung cancer model.
- To determine if endostatin's anti-angiogenic properties enhance HSV-1's oncolytic effect.
Main Methods:
- Development of a genetically modified HSV-1 expressing endostatin (HSV-Endo).
- Evaluation of HSV-Endo in murine models of pulmonary metastases and orthotopic flank tumors.
- Comparison of tumor burden and microvessel density between HSV-Endo and control virus treatment groups.
Main Results:
- HSV-Endo treatment resulted in significantly reduced tumor burden compared to the control virus.
- A significant reduction in tumor microvessel density was observed in the HSV-Endo group.
- The anti-angiogenic action of endostatin appeared to augment the anti-tumor effects of HSV-1.
Conclusions:
- Endostatin-expressing HSV-1 demonstrates improved anti-tumor efficacy in a lung cancer model.
- Combining oncolytic virotherapy with anti-angiogenic gene therapy is a promising strategy for cancer treatment.
- Further research into HSV-Endo holds potential for novel lung cancer therapies.
